Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

how good communication prevents complaints

The ASCOT trial is likely to have a 'significant impact' on new NICE and British Hypertension Society guidelines for hypertension, a preliminary review has concluded.

The Expert Advisory Committee review, by representatives of NICE, the BHS and the Blood Pressure Association, has confirmed the need for a wider evaluation of hypertension guidance.

The new review, which will also involve the National Collaborating Centre for Chronic Conditions, will consider evidence from ASCOT that ?-blockers should be dropped as first-line therapy.

Professor Peter Littlejohns, NICE clinical and public health director, said: 'The new data considered by the hypertension expert advisory committee are, in their view, likely to have a significant impact on the recommendations in the existing NICE guideline and also in the BHS guideline relating to pharmacological therapy to manage hypertension.

'Accordingly, we have asked the NCC-CC to work with the BHS to begin the review process immediately so that we are in a position to provide GPs with clear guidance as soon as

possible.'

Professor Bryan Williams, chair of the BHS NHS guideline development group, said: 'This is a significant development in terms of ensuring that the many thousands of people with hypertension will be able to access treatments based on the most up-to-date clinical evidence.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say